179314-60-4Relevant articles and documents
COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS
-
, (2016/04/20)
The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
6,5-Fused aromatic ring systems having enhanced phosphodiesterae IV inhibitory activity
-
, (2008/06/13)
Novel compounds which are effective PDE IV inhibitors are disclosed. The compounds possess improved PDE IV inhibition as compared to theophylline or rolipram, with improved selectivity with regard to, e.g., PDE V inhibition. The present invention includes compounds of Formula I: wherein:rings "A" and "B" can be saturated, unsaturated or partially unsaturated;X1 is selected from CH, C-Cl, or N;X2 is selected from CR12 or N;X3 is selected from CH or N;X4 is selected from CH or N;P1, P2 are independently selected from CH,O or N or NH;M is selected from CH, C, or N;Q is C1-C3 alkyl or -CH=CH-;R6 is selected from -C(R9)3, CH(R9)2, or C3-C8 cycloalkyl;R7 is selected from -OH, -O-CO-CH3, -SH, or -CHO;R8 is selected from -C(R9)3, -CH(R9)2, -C3-C8-cycloalkyl, or -CH2-C4-C6-cycloalkyl;R10 is selected from C1-C3-pyridyl, C3H6OH,-C= C-, Br, -C=C-CH2OH, isopropyl, hydrogen, andR11 is selected from H, -OH, -O-C3-C8-cycloalkyl, -NH2, -NH-C1-C3-alkyl, -SH, -NH-C3-C8-cycloalkyl, -Z-pyridyl, -Z-trienyl, and -Z-CH2OH;R12 is selected from -SH, H, halogen or lower alkyl;R9 is lower alkyl; andZ is selected from ethyl, and -C=C-.
